JLPC(SH:600513)2022-10-21 16:00Financial Performance - The company's revenue for Q3 2022 reached ¥515,595,632.46, representing a 25.50% increase compared to the same period last year[3] - Net profit attributable to shareholders was ¥33,630,926.08, reflecting a 6.51% year-over-year growth[3] - The net profit excluding non-recurring gains and losses was ¥33,002,691.37, up by 6.86% from the previous year[3] - Total operating revenue for the first three quarters of 2022 reached ¥1,412,283,517.33, an increase of 20.7% compared to ¥1,169,942,600.71 in the same period of 2021[12] - Net profit for the third quarter of 2022 was ¥120,423,496.23, representing a 19.7% increase from ¥100,536,929.89 in Q3 2021[13] - The total comprehensive income attributable to the parent company for the third quarter of 2022 was CNY 99,288,084.16, an increase from CNY 85,963,003.88 in the same period of 2021, representing a growth of approximately 15.5%[14] Assets and Liabilities - The total assets as of September 30, 2022, amounted to ¥2,561,269,571.57, an increase of 8.77% from the end of the previous year[3] - The total assets of the company as of Q3 2022 amounted to ¥2,561,269,571.57, an increase from ¥2,354,796,481.05 at the end of Q3 2021[11] - The company's total liabilities reached ¥1,193,313,483.56, up from ¥1,073,869,781.09 in the previous year[11] - The equity attributable to shareholders of the parent company increased to ¥1,222,419,476.70, compared to ¥1,158,113,000.72 in Q3 2021[11] Cash Flow - The company reported a net cash flow from operating activities of -¥28,877,037.46 for the year-to-date, indicating a significant decline of 143.72%[4] - The net cash flow from operating activities for the first three quarters of 2022 was negative CNY 28,877,037.46, compared to a positive CNY 66,054,135.50 in the same period of 2021, reflecting a significant decline[15] - Cash inflow from operating activities totaled CNY 1,579,652,825.75 for the first three quarters of 2022, compared to CNY 1,394,547,714.80 in 2021, marking an increase of approximately 13.3%[15] - The cash outflow from operating activities increased to CNY 1,608,529,863.21 in 2022 from CNY 1,328,493,579.30 in 2021, representing a rise of about 21.1%[15] - The net cash flow from investing activities for the third quarter of 2022 was negative CNY 162,644,694.93, an improvement from negative CNY 184,590,008.16 in the same period of 2021[16] - The cash inflow from financing activities for the first three quarters of 2022 was CNY 567,510,000.00, compared to CNY 409,000,000.00 in 2021, indicating an increase of approximately 38.8%[16] - The company’s cash flow from financing activities included CNY 554,500,000.00 in borrowings received, which was an increase from CNY 359,000,000.00 in the previous year[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,676[5] - The largest shareholder, Jiangsu Lianhuan Pharmaceutical Group Co., Ltd., holds 37.86% of the shares[6] Research and Development - Research and development expenses increased to ¥58,937,451.98 in Q3 2022, up 50.5% from ¥39,119,611.11 in Q3 2021[13] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[12] Earnings Per Share - Basic earnings per share for the quarter were ¥0.12, a 9.09% increase year-over-year[3] - The basic earnings per share for the third quarter of 2022 was CNY 0.35, up from CNY 0.30 in the previous year, indicating a growth of about 16.7%[14] Operating Costs and Profitability - Total operating costs for the first three quarters of 2022 were ¥1,272,183,006.75, up 20.8% from ¥1,053,144,292.42 in the previous year[12] - The company's gross profit margin improved to approximately 10.0% in the first three quarters of 2022, compared to 9.9% in the same period last year[12] - The company recorded government subsidies amounting to ¥1,253,560.08 during the reporting period[4]